• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SNDL Reports Second Quarter 2023 Financial and Operational Results

    8/14/23 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $SNDL alert in real time by email

    The Company achieves record net revenue and gross margin results since its inception

    CALGARY, AB, Aug. 14, 2023 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the second quarter ended June 30, 2023. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.

    SNDL Inc. Logo (CNW Group/Sundial Growers Inc.)

    SNDL has also posted a supplemental investor presentation on its website, which can be found at https://sndl.com.

    SECOND QUARTER 2023 FINANCIAL AND OPERATIONAL HIGHLIGHTS

    • Net revenue for the second quarter of 2023 of $244.5 million, compared to $223.7 million in the corresponding period of 2022, an increase of 9.3%. This marks an all-time high for the Company, underscoring SNDL's strategic initiatives and operational enhancements, which have led to financial and operational improvements.
      • Liquor Retail: Net revenue of $151.7 million for the second quarter of 2023, an increase of 2.1% compared to the prior year.
      • Cannabis Retail: Net revenue of $71.9 million for the second quarter of 2023, an increase of 13.2% compared to the prior year.
      • Cannabis Operations: Net revenue of $20.9 million for the second quarter of 2023, an increase of 81% compared to the prior year.
    • Record gross margin of $51.9 million in the second quarter of 2023, compared to $43.1 million in the second quarter of 2022. The 21% increase in gross margin year-over-year is driven by cost-saving measures, supply chain efficiencies, improved pricing strategies, economies of scale, and product mix optimization.
    • Net loss of $33.2 million for the second quarter of 2023, compared to a $74.0 million net loss in the second quarter of 2022. The loss was driven by one-time events, including the Valens Company ("Valens") integration and related costs, as well as by realized losses from equity investments.
    • Adjusted EBITDA of $2.2 million for the second quarter of 2023, compared to a loss of $25.9 million from the second quarter of 2022, reflecting the improvement in the financial performance of SNDL's operating segments along with synergies realized through the Company's vertical integration strategies.
    • During the second quarter of 2023, a total of $8.8 million cash was used in operating activities, compared to $17.9 million in the same quarter of last year, an improvement of 51%, showcasing the Company's enhanced operational efficiency.
    • SNDL currently has five credit exposures in the SunStream portfolio following the monetization of a credit exposure in July 2023. The current portfolio includes one credit under a court-supervised receivership process and another in active restructuring negotiations.
    • $754 million of unrestricted cash, marketable securities and investments, and no outstanding debt at June 30, 2023, resulting in a net book value per share of $4.86; and $182.6 million of unrestricted cash at August 11, 2023. SNDL has not raised cash through share offerings since June 2021.

    "Our incredible two-year journey from less than $10 million of net revenue and negative gross margin in Q2 2021 to our current trajectory of reaching an expected $1 billion in annual revenue and continued gross margin growth in 2023 is a testament to our team's commitment to becoming a leader in Canadian regulated products," said Zach George, Chief Executive Officer of SNDL. "We have taken decisive steps to simplify operations throughout our business segments with a sharp focus on the goal of reaching profitability in 2024. In Liquor Retail, we are capitalizing on margin accretive product opportunities and modest expansion. In Cannabis Retail, our data licensing program is driving improved profitability and supplier relationships, and we look to enhance consumer engagement through new loyalty capabilities. In our Cannabis Operations, we have taken aggressive cost-cutting measures, streamlined manufacturing operations, and reduced reliance on high-cost cultivation. During this process, we have maintained cannabis sales momentum and are actively exploring B2B and international opportunities. We have also simplified our investment portfolio by divesting from securities, prioritizing the opportunity to return capital to our shareholders."

    "Over the last two years, SNDL has grown both organically and by acquisition while our leaders have implemented bold changes throughout the business," added George. "We believe that we now have the requisite scale and platform optionality to create sustainable shareholder value. We expect our Canadian retail network to continue to grow at a modest pace while our internal focus on optimization is in the early stages of producing tangible results. We look forward to updating investors on the closing of the Nova transaction, and events related to our SunStream portfolio as we focus on delivering improved performance in the second half of 2023."

    SECOND QUARTER 2023 KEY FINANCIAL METRICS

    OPERATING SEGMENTS

















    ($000s)



    Liquor

    Retail

    Cannabis

    Retail

    Cannabis

    Operations

    Investments

    Corporate



    Total

    Three months ended June 30, 2023













    Net revenue



    151,690

    71,881

    20,940

    —

    —



    244,511

    Gross margin



    35,360

    17,780

    (1,207)

    —

    —



    51,933

    Earnings (loss) from Operations



    8,207

    2,340

    (14,134)

    (1,660)

    (24,242)



    (29,489)



















    Three months ended June 30, 2022

















    Net revenue



    148,637

    63,494

    11,564

    —

    —



    223,695

    Gross margin



    33,528

    13,897

    (4,346)

    —

    —



    43,079

    Earnings (loss) from Operations



    11,288

    1,476

    (8,293)

    (69,973)

    (15,914)



    (81,416)

     

    SECOND QUARTER 2023 RESULTS

    SNDL's business is operated and reported in four segments: Liquor Retail, Cannabis Retail, Cannabis Operations and Investments. 

    Liquor Retail

    SNDL is Canada's largest private sector liquor retailer, operating 170 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond", "Liquor Depot" and "Ace Liquor".

    • Net revenue for Liquor Retail sales for the three banners combined was $151.7 million for the second quarter of 2023, an increase of 2.1% compared to the second quarter of 2022.
    • Same stores sales increased 1.7% across all liquor banners, with Liquor Depot and Ace Liquor seeing 5.6% and 2.8% in same-store sale increases, respectively.
    • Gross margin in the Liquor Retail segment was $35.4 million, or 23.3% of sales in the second quarter of 2023, compared to $33.5 million, or 22.6% of sales, in the second quarter of 2022. The 5.5% gross margin growth is mainly driven by procurement productivity and product mix management initiatives.
    • Preferred label sales, which are a substantial driver of gross margin growth, increased 28% compared to the second quarter of 2022 and 22% compared to the first quarter of 2023.
    • SNDL's liquor banners' market share in Alberta was approximately 18% in the second quarter of 2023, with Wine and Beyond representing approximately 3% from only 11 stores in the province, showcasing the continued success of the banner. Sales at the Wine and Beyond in Kelowna, British Columbia, continue to increase year-over-year, further validating the banner's expansion strategy into Saskatchewan in 2024.
    • SNDL expects to launch an e-commerce platform for its Liquor Retail banner, Wine and Beyond, which presents significant opportunities to drive accretive revenues. It is expected to provide the Company with a scalable and adaptable platform to expand its market presence, increase customer engagement, and capitalize on the growing trend of online shopping for liquor products. The launch date is scheduled for the third quarter of 2023.
    • As of August 11, 2023, the Ace Liquor store count is 138, the Liquor Depot store count is 20, and the Wine and Beyond store count is 12.

    Cannabis Retail

    With its ownership interest in Nova, SNDL is Canada's largest private-sector cannabis retailer, operating 196 locations under its four retail banners: Value Buds, Spiritleaf, Superette, and Firesale Cannabis. SNDL's Cannabis Retail strategy is based on several factors, including the quality of its store locations, the range of products it offers, and the unique experiences it provides customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.

    On July 25, 2023, SNDL and Nova announced that while all other provincial approvals have been received, the continued review by one provincial regulator has necessitated the extension of the outside date for the closing of the previously-announced strategic partnership (the "Transaction"). SNDL and Nova anticipate that the Transaction will close on or before August 25, 2023, subject to the receipt of regulatory approval and the amendment to certain terms of the Transaction that are mutually satisfactory to SNDL and Nova.

    • Net revenue from the Cannabis Retail segment for the second quarter of 2023 was $71.9 million, compared to $63.5 million in the second quarter of 2022, a 13.2% increase year-over-year and a record for the segment since SNDL diversified into Cannabis Retail.
    • Same stores sales for the second quarter of 2023 increased 3.3% across all Cannabis Retail banners, compared to the same period in the year prior. Nova's same store sales increased 38% for the period.
    • Gross margin of $17.8 million, or 24.7% of sales, up by close to 28% compared to the second quarter of 2022, showcasing the Company's efforts in continued margin expansion initiatives.
    • In the first half of 2023, SNDL took proactive steps to optimize its proprietary data licensing program for the Cannabis Retail segment, aiming to create mutually beneficial results for its retail operations and licensed producer partners. This margin accretive opportunity has resulted in revenue for the second quarter of 2023 of $2.7 million, compared to $1.3 million in the second quarter of 2022, and represents growth of 80% compared to the first quarter of 2023. By leveraging the volume of Nova's retail locations and the Company's access to high-quality analytics, it expects to deliver continued successful outcomes for its partners and drive top-line revenue and margin growth.
    • The Company partnered with Nova for Value Buds' private label products, and sales of Value Buds products represented approximately 6.6% of total 28-gram sales and 18.0% of 14-gram sales in Value Buds locations nationwide.
    • As of August 11, 2023, the Spiritleaf store count is 98 (21 corporate stores and 77 franchise stores), the Value Buds store count is 91 corporate stores, the Superette store count is five corporate stores, and the Firesale store count is two corporate stores.

    Cannabis Operations

    SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities, premium cultivation and manufacturing facilities, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.

    • Net revenue from the Cannabis Operations segment for the second quarter of 2023 was $20.9 million, an 81% increase compared to the second quarter of 2022, and a 9% increase compared to the first quarter of 2023.
    • Gross margin of negative $1.2 million in the second quarter of 2023, compared to negative $4.3 million in the second quarter of 2022, and negative $9.5 million in the first quarter of 2023. The improved results showcase the Company's focus on bolstering margins through increased product distribution and streamlining the Cannabis Operations segment.
    • In the first half of 2023, SNDL implemented aggressive cost-cutting measures and improved manufacturing efficiency. A key initiative involved right-sizing cannabis cultivation in Olds, Alberta to focus on producing premium products.
    • Subsequently, SNDL successfully centralized most manufacturing activities and consolidated processing, labelling, and excising at its Kelowna facilities. This move optimizes resource allocation and streamlines operations to significantly reduce costs.
    • Following the Valens acquisition, the Company underwent a meticulous evaluation of its portfolio, focusing on higher-margin brands and products. SNDL's vertical integration capabilities facilitate informed and data-driven product portfolio decisions. This strategic alignment enables SNDL to effectively enhance overall market positioning and product offerings.
    • Market share in owned retail continues to scale through the Company's vertical integration strategy. Driving increased owned retail share is a key focus for the Company and a meaningful contributor to overall margin and profit growth. As a supplement to this strategy, SNDL partnered with ColdHaus Direct ("ColdHaus") in May of 2023 to manage the Company's in-market sales and logistics execution for its branded cannabis products.

    Investments

    • As of the end of the second quarter of 2023, the Company had deployed capital on a portfolio of cannabis-related investments with a carrying value of $569.0 million, including $532.8 million through the SunStream Bancorp Inc. joint venture ("SunStream").
    • For the second quarter of 2023, the investment portfolio generated a net loss of $1.5 million, mainly driven by interest and fee revenue of $3.2 million, and an investment loss of $3.8 million on marketable securities. To streamline its business operations, SunStream made the strategic decision to divest certain cannabis investments, and as part of this process, the Company realized losses. The realized loss on marketable securities and the reversal of the unrealized loss on marketable securities was due to the disposition of shares in cannabis-related investments.
    • At the end of the second quarter of 2023, SunStream's credit portfolio comprised six investments: Jushi Holdings, SKYMINT Brands ("Skymint"), Ascend Wellness Holdings, Parallel Inc. ("Parallel"), Columbia Care Inc., and AFC Gamma, Inc. The AFC Gamma, Inc. investment was monetized above carrying value subsequent to the end of the second quarter of 2023.
    • SunStream is actively implementing a stock-exchange compliant structure to facilitate participation in US cannabis companies. In connection, SunStream is exploring the restructuring and transfer of certain credit interests in Skymint and Parallel to a new US holding entity ("Sunstream USA"). The SunStream USA structure is expected to allow SNDL to participate in SunStream assets while complying with all US federal and state laws. This SunStream USA structure is anticipated to include the issuance of securities upon the equitization of specific credit instruments held by SunStream. In turn, SNDL would hold non-voting shares in SunStream USA, with the right to exchange such shares into common shares in the future, if certain conditions are met. As such, the Sunstream USA structure is expected to allow SNDL to participate in SunStream assets through a revamped capital structure. The proposed Sunstream USA structure will be reviewed by Nasdaq, as the relevant listing authority for SNDL, prior to its execution. SNDL anticipates providing further details on progress with the Skymint and Parallel restructuring initiatives in the third quarter of 2023.


    Three months ended

    June 30



    Six months ended

    June 30

    ($000s)

    2023

    2022



    2023

    2022

    Interest and fee revenue











    Interest revenue from investments at amortized cost

    922

    818



    1,928

    1,813

    Interest and fee revenue from investments at Fair

    Value Through Profit or Loss

    250

    543



    874

    2,659

    Interest revenue from cash

    2,014

    1,216



    4,595

    1,966

     Total interest and fee revenue

    3,186

    2,577



    7,397

    6,438

    Investment revenue (loss)











    Realized (losses) gains

    (48,988)

    265



    (92,792)

    389

    Unrealized gains (losses)

    45,182

    (35,338)



    84,100

    (53,172)

     Total investment revenue/(loss)

    (3,806)

    (35,073)



    (8,692)

    (52,783)













    Share of profit (loss) of equity-accounted investees

    (936)

    (37,978)



    8,580

    (33,887)

    Total investment activities

    (1,556)

    (70,474)



    7,285

    (80,232)

     

    Liquidity Position

    • As at June 30, 2023, and August 11, 2023, the Company had unrestricted cash balances of $185.5 million and $182.6 million, respectively, and a total of approximately 260 million shares outstanding as at August 11, 2023.
    • The Company's share repurchase program continues to be available to lower the outstanding share float and increase the earnings per share for shareholders. SNDL will continue to assess opportunities to utilize the program to the extent that management believes SNDL's shares are undervalued. For the three months ended June 30, 2023, the Company did not purchase or cancel common shares.

    STRATEGIC AND ORGANIZATIONAL UPDATE

    SNDL remains focused on building long-term shareholder value through vertical integration, the accretive deployment of cash resources, expansion of its retail distribution network, the further streamlining of the Company's operating structure, and enhanced offerings of high-quality brands within the Liquor Retail, Cannabis Retail and Cannabis Operations segments.

    Integration Initiatives

    The Company has achieved $18.2 million in annualized cost savings since the Valens acquisition in January 2023. These initiatives surpass the Company's original $10 million cost savings target. Most of the cost savings have been realized through SG&A, public company costs, as well as supply chain consolidation and operational efficiency. By 2024, run-rate synergies are expected to exceed $30 million annually, and proceeds from asset sales are expected to total $9 million.

    The integration work has allowed the Company to undertake a comprehensive organizational design update, restructuring certain departments to achieve scale, support growth, and reinforce key initiatives. The organizational design work supports a more efficient structuring of SNDL's shared service teams to realize additional cost savings and enable targeted focus on key initiatives, such as loyalty, e-commerce, increasing market share within owned retail, and manufacturing, cultivation and processing improvements.

    The Company's integration initiatives are critical to SNDL's vision of establishing Canada's largest regulated products platform and generating sustainable free cash flow.

    SNDL's strategy is predicated on the below key objectives:

    • Generate positive cash flow from all operating segments by 2024.
    • Maximize the profitability and sustainability of SNDL's Liquor Retail segment.
    • Establish a dominant multi-banner cannabis retail platform with a national presence.
    • Streamline SNDL's cannabis production and drive profitable market share.

    This press release is intended to be read in conjunction with the Company's Financial Statements and Notes for the period ended June 30, 2023, and the accompanying Management's Discussion and Analysis ("MD&A"). These reports are available under the Company's profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.

    CONFERENCE CALL

    The Company will hold a conference call and webcast at 10:30 a.m. EST (8:30 a.m. MST) on Monday, August 14, 2023.

    WEBCAST ACCESS

    To access the live webcast of the call, please visit the following link:

    https://services.choruscall.ca/links/sndl2023q2.html

    REPLAY

    A telephone replay will be available for one month. To access the replay, dial:

    Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010

    When prompted, enter Replay Access Code: 0323#

    The webcast archive will be available for three months via the link provided above.

    ABOUT SNDL INC. 

    SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL."

    SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. SNDL is a licensed cannabis producer and one of the largest vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Bon Jak, Spiritleaf Selects, Versus Cannabis, Value Buds, Vacay, Grasslands and Superette. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry. For more information on SNDL, please go to https://sndl.com/.

    Forward-Looking Information Cautionary Statement

    This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, demand for the Company's products, the Company's ability to achieve profitability or its goal of sustainable, positive gross margin and positive free cash flow, the development of the legal cannabis industry, performance of the Company's investments, including through the SunStream joint venture, any potential forms of shareholder value creation, the ability to realize expected cost savings and the expansion of product offerings, brand and market share and retail networks, and the closing, integration and realization of expected benefits of, as applicable, the acquisition of The Valens Company, Zenabis and Superette. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "likely", "outlook", "forecast", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Item 3.D.—Risk Factors" in the Company's annual report on Form 20-F, filed with the Securities and Exchange Commission ("SEC") on April 24, 2023, and the risk factors included in our other SEC filings for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

    Condensed Consolidated Interim Statement of Loss and Comprehensive Loss

    (Unaudited - expressed in thousands of Canadian dollars, except per share amounts)





    Three months ended

    June 30



    Six months ended

    June 30





    2023



    2022



    2023



    2022

    Gross revenue



    257,425



    227,557



    470,324



    247,684

    Excise taxes



    12,914



    3,862



    23,361



    6,392

    Net revenue



    244,511



    223,695



    446,963



    241,292

    Cost of sales



    188,922



    174,291



    347,071



    188,617

    Inventory impairment and obsolescence



    4,291



    3,871



    13,468



    5,852

    Gross margin before fair value adjustments



    51,298



    45,533



    86,424



    46,823

    Change in fair value of biological assets



    (1,413)



    (388)



    (4,948)



    3,302

    Change in fair value realized through inventory



    2,048



    (2,066)



    2,998



    (3,627)

    Gross margin



    51,933



    43,079



    84,474



    46,498



















    Interest and fee revenue



    3,421



    2,577



    7,632



    6,438

    Investment loss



    (4,020)



    (35,073)



    (9,189)



    (52,783)

    Share of profit (loss) of equity-accounted investees



    (936)



    (37,978)



    8,580



    (33,887)



















    General and administrative



    52,727



    40,293



    101,300



    50,975

    Sales and marketing



    4,104



    3,132



    7,490



    4,243

    Research and development



    20



    390



    160



    485

    Depreciation and amortization



    13,443



    8,800



    29,911



    9,539

    Share-based compensation



    3,893



    438



    6,102



    4,642

    Restructuring costs



    4,042



    (882)



    5,578



    (882)

    Asset impairment



    1,658



    1,850



    2,465



    1,850

    Loss from operations



    (29,489)



    (81,416)



    (61,509)



    (104,586)



















    Transaction costs



    (173)



    7,938



    (2,213)



    1,457

    Finance costs, net



    (2,458)



    (26,505)



    (7,631)



    (26,444)

    Change in estimate of fair value of derivative warrants



    2,240



    23,656



    7,042



    15,356

    Foreign exchange gain (loss)



    (31)



    161



    (194)



    11

    Gain (loss) on disposition of assets



    (77)



    402



    (261)



    402

    Loss before income tax



    (29,988)



    (75,764)



    (64,766)



    (113,804)

    Income tax recovery



    —



    1,791



    —



    1,791

    Net loss from continuing operations



    (29,988)



    (73,973)



    (64,766)



    (112,013)

    Net loss from discontinued operations



    (3,170)



    —



    (4,535)



    —

    Net loss



    (33,158)



    (73,973)



    (69,301)



    (112,013)



















    Equity-accounted investees - share of other

    comprehensive income (loss)



    (11,621)



    12,727



    (12,006)



    5,994

    Gain on translation of foreign operations



    (5)



    —



    —



    —

    Comprehensive loss



    (44,784)



    (61,246)



    (81,307)



    (106,019)



















    Net loss from continuing operations attributable to:

















    Owners of the Company



    (29,350)



    (73,301)



    (63,553)



    (111,205)

    Non-controlling interest



    (638)



    (672)



    (1,213)



    (808)





    (29,988)



    (73,973)



    (64,766)



    (112,013)

    Net income (loss) attributable to:

















    Owners of the Company



    (32,520)



    (73,301)



    (68,088)



    (111,205)

    Non-controlling interest



    (638)



    (672)



    (1,213)



    (808)





    (33,158)



    (73,973)



    (69,301)



    (112,013)

    Comprehensive income (loss) attributable to:

















    Owners of the Company



    (44,146)



    (60,574)



    (80,094)



    (105,211)

    Non-controlling interest



    (638)



    (672)



    (1,213)



    (808)





    (44,784)



    (61,246)



    (81,307)



    (106,019)

     

     

    Condensed Consolidated Interim Statement of Financial Position

    (Unaudited - expressed in thousands of Canadian dollars)

    As at



    June 30, 2023



    December 31, 2022











    Assets









    Current assets









    Cash and cash equivalents



    185,455



    279,586

    Restricted cash



    19,456



    19,338

    Marketable securities



    3,535



    21,926

    Accounts receivable



    32,661



    22,636

    Biological assets



    1,330



    3,477

    Inventory



    160,407



    127,782

    Prepaid expenses and deposits



    21,792



    10,110

    Investments



    23,038



    6,552

    Assets held for sale



    8,391



    6,375

    Net investment in subleases



    3,656



    3,701





    459,721



    501,483

    Non-current assets









    Long-term deposits



    9,766



    8,584

    Right of use assets



    136,947



    134,154

    Property, plant and equipment



    181,841



    143,409

    Net investment in subleases



    18,918



    19,618

    Intangible assets



    74,446



    74,885

    Investments



    9,638



    90,702

    Equity-accounted investees



    532,818



    519,255

    Goodwill



    147,680



    67,260

    Total assets



    1,571,775



    1,559,350











    Liabilities









    Current liabilities









    Accounts payable and accrued liabilities



    62,557



    48,153

    Lease liabilities



    35,982



    30,206

    Derivative warrants



    3,960



    11,002





    102,499



    89,361

    Non-current liabilities









    Lease liabilities



    136,136



    139,625

    Other liabilities



    5,252



    2,709

    Total liabilities



    243,887



    231,695











    Shareholders' equity









    Share capital



    2,365,845



    2,292,810

    Warrants



    2,260



    2,260

    Contributed surplus



    73,636



    68,961

    Contingent consideration



    2,279



    2,279

    Accumulated deficit



    (1,156,279)



    (1,091,999)

    Accumulated other comprehensive income



    20,182



    32,188

    Total shareholders' equity



    1,307,923



    1,306,499

    Non-controlling interest



    19,965



    21,156

    Total liabilities and shareholders' equity



    1,571,775



    1,559,350

     

     

    Condensed Consolidated Interim Statement of Cash Flows

    (Unaudited - expressed in thousands of Canadian dollars)



    Three months ended

    June 30



    Six months ended

    June 30



    2023

    2022



    2023



    2022

    Cash provided by (used in):













    Operating activities













    Net loss for the period

    (33,158)

    (73,973)



    (69,301)



    (112,013)

    Adjustments for:













    Income tax recovery

    —

    (1,791)



    —



    (1,791)

    Interest and fee revenue

    (3,421)

    (2,577)



    (7,632)



    (6,438)

    Change in fair value of biological assets

    1,413

    388



    4,948



    (3,302)

    Share-based compensation

    3,893

    438



    6,102



    4,642

    Depreciation and amortization

    14,674

    10,538



    32,933



    12,977

    Loss (gain) on disposition of assets

    77

    (402)



    261



    (402)

    Inventory obsolescence

    4,291

    3,871



    13,468



    5,852

    Finance costs

    2,458

    26,505



    7,631



    26,444

    Change in estimate of fair value of derivative warrants

    (2,240)

    (23,656)



    (7,042)



    (15,356)

    Unrealized foreign exchange loss (gain)

    (72)

    19



    (24)



    35

    Asset impairment

    1,658

    1,850



    2,465



    1,850

    Share of (profit) loss of equity-accounted investees

    936

    37,978



    (8,580)



    33,887

    Loss on settlement of marketable securities

    48,988

    —



    92,792



    —

    Unrealized (gain) loss on marketable securities

    (44,968)

    35,338



    (83,603)



    53,172

    Additions to marketable securities

    —

    (2,899)



    —



    (3,500)

    Proceeds from settlement of marketable securities

    3,437

    —



    3,463



    —

    Income distributions from equity-accounted investees

    —

    —



    —



    685

    Interest received

    3,217

    2,084



    6,920



    5,799

    Change in non-cash working capital

    (14,193)

    (31,584)



    (56,755)



    (46,434)

    Net cash used in operating activities from continuing operations

    (13,010)

    (17,873)



    (61,954)



    (43,893)

    Net cash provided by operating activities from discontinued operations

    4,167

    —



    4,314



    —

    Net cash used in operating activities

    (8,843)

    (17,873)



    (57,640)



    (43,893)

    Investing activities













    Additions to property, plant and equipment

    (1,247)

    (3,554)



    (2,641)



    (4,535)

    Additions to intangible assets

    (39)

    1



    (56)



    (55)

    Additions to investments

    125

    337



    (702)



    (14,094)

    Additions to equity-accounted investees

    (9,443)

    (36,880)



    (16,989)



    (94,200)

    Proceeds from disposal of property, plant and equipment

    55

    4,000



    137



    4,000

    Acquisitions, net of cash acquired

    —

    —



    3,695



    (31,149)

    Change in non-cash working capital

    1,586

    294



    1,127



    259

    Net cash used in investing activities from continuing operations

    (8,963)

    (35,802)



    (15,429)



    (139,774)

    Net cash used in investing activities from discontinued operations

    —

    —



    —



    —

    Net cash used in investing activities

    (8,963)

    (35,802)



    (15,429)



    (139,774)

    Financing activities













    Change in restricted cash

    (76)

    2,541



    (118)



    7,607

    Payments on lease liabilities, net

    (10,116)

    (9,177)



    (19,607)



    (9,624)

    Repurchase of common shares, net of costs

    —

    (2,053)



    (1,536)



    (2,053)

    Repayment of long-term debt

    —

    —



    —



    (10,000)

    Change in non-cash working capital

    200

    2,170



    199



    2,116

    Net cash used in financing activities from continuing operations

    (9,992)

    (6,519)



    (21,062)



    (11,954)

    Net cash used in financing activities from discontinued operations

    —

    —



    —



    —

    Net cash used in financing activities

    (9,992)

    (6,519)



    (21,062)



    (11,954)

    Change in cash and cash equivalents

    (27,798)

    (60,194)



    (94,131)



    (195,621)

    Cash and cash equivalents, beginning of period

    213,253

    422,824



    279,586



    558,251

    Cash and cash equivalents, end of period

    185,455

    362,630



    185,455



    362,630

     

    SPECIFIED FINANCIAL MEASURES

    Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS. These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team. 

    ADJUSTED EBITDA

    Adjusted EBITDA is a non-IFRS measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors, analysts, and others to aid in understanding and evaluating the Company's operating results in a manner similar to its management team. Adjusted EBITDA is defined as net income (loss) from continuing operations before finance costs, depreciation and amortization, accretion expense, income tax recovery and excluding changes in fair value of biological assets, changes in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, changes in fair value of derivative warrants, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, inventory impairment (recovery) and obsolescence, restructuring costs and transaction costs. The Company presents both consolidated or total Adjusted EBITDA and Adjusted EBITDA by operating segment.

    OPERATING SEGMENTS











    ($000s)

    Liquor

    Retail

    Cannabis

    Retail

    Cannabis

    Operations

    Investments

    Corporate

    Total

    Three months ended June 30, 2023













    Net earnings (loss)

    6,714

    1,221

    (13,831)

    (1,917)

    (22,175)

    (29,988)

    Adjustments













    Finance costs

    1,490

    1,111

    (400)

    257

    —

    2,458

    Change in estimate of fair value of

    derivative warrants

    —

    —

    —

    —

    (2,240)

    (2,240)

    Depreciation and amortization

    8,161

    3,361

    650

    —

    1,271

    13,443

    Change in fair value of biological assets

    —

    —

    1,413

    —

    —

    1,413

    Change in fair value realized through

    inventory

    —

    —

    (2,048)

    —

    —

    (2,048)

    Unrealized foreign exchange (gain) loss

    (2)

    —

    (70)

    —

    —

    (72)

    Unrealized (gain) loss on marketable

    securities

    —

    —

    214

    (45,182)

    —

    (44,968)

    Realized loss on marketable securities

    —

    —

    —

    49,093

    —

    49,093

    Share-based compensation

    —

    15

    —

    —

    3,878

    3,893

    Asset impairment

    —

    458

    1,200

    —

    —

    1,658

    Loss (gain) on disposition of PP&E

    —

    5

    72

    —

    —

    77

    Cost of sales non-cash component (1)

    —

    —

    969

    —

    —

    969

    Inventory impairment (recovery) and

    obsolescence

    —

    —

    4,291

    —

    —

    4,291

    Restructuring costs

    —

    —

    1,282

    —

    2,760

    4,042

    Transaction costs

    —

    —

    —

    —

    173

    173

    Adjusted EBITDA

    16,363

    6,171

    (6,258)

    2,251

    (16,333)

    2,194

     (1) Cost of sales non-cash component is comprised of depreciation expense

     

     

    OPERATING SEGMENTS











    ($000s)

    Liquor

    Retail

    Cannabis

    Retail

    Cannabis

    Operations

    Investments

    Corporate

    Total

    Three months ended June 30, 2022













    Net earnings (loss)

    8,379

    447

    (8,036)

    (90,487)

    15,724

    (73,973)

    Adjustments













    Finance costs

    2,874

    1,070

    195

    22,305

    61

    26,505

    Change in estimate of fair value of

    derivative warrants

    —

    (56)

    —

    —

    (23,600)

    (23,656)

    Depreciation and amortization

    5,315

    3,370

    —

    —

    115

    8,800

    Income tax recovery

    —

    —

    —

    (1,791)

    —

    (1,791)

    Change in fair value of biological assets

    —

    —

    388

    —

    —

    388

    Change in fair value realized through

    inventory

    —

    —

    2,066

    —

    —

    2,066

    Unrealized foreign exchange (gain) loss

    9

    —

    10

    —

    —

    19

    Unrealized (gain) loss on marketable

    securities

    —

    —

    —

    35,338

    —

    35,338

    Share-based compensation

    —

    (180)

    —

    —

    618

    438

    Asset impairment

    —

    —

    1,850

    —

    —

    1,850

    Loss (gain) on disposition of PP&E

    35

    15

    (452)

    —

    —

    (402)

    Cost of sales non-cash component (1)

    —

    —

    3,440

    —

    —

    3,440

    Inventory impairment (recovery) and

    obsolescence

    —

    —

    3,871

    —

    —

    3,871

    Restructuring costs

    —

    —

    —

    (882)

    —

    (882)

    Transaction costs

    —

    —

    —

    —

    (7,938)

    (7,938)

    Adjusted EBITDA

    16,612

    4,666

    3,332

    (35,517)

    (15,020)

    (25,927)

    (1) Cost of sales non-cash component is comprised of depreciation expense

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/sndl-reports-second-quarter-2023-financial-and-operational-results-301899495.html

    SOURCE Sundial Growers Inc.

    Get the next $SNDL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNDL

    DatePrice TargetRatingAnalyst
    9/3/2025$5.00Buy
    Alliance Global Partners
    7/17/2024Speculative Buy
    Canaccord Genuity
    8/16/2022$5.00Hold → Speculative Buy
    Canaccord Genuity
    5/3/2022$0.60 → $0.70Underperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $SNDL
    SEC Filings

    View All

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    1/7/26 4:32:18 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by SNDL Inc.

    6-K - SNDL Inc. (0001766600) (Filer)

    12/15/25 4:36:51 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 144 filed by SNDL Inc.

    144 - SNDL Inc. (0001766600) (Subject)

    12/12/25 9:28:29 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL & 1CM Provide Update Regarding Arrangement

    EDMONTON, Alberta and TORONTO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") announce that they have entered into an amended and restated arrangement agreement (the "A&R Arrangement Agreement") dated December 15, 2025. The A&R Arrangement Agreement amends and restates the arrangement agreement dated April 9, 2025 between 1CM and SNDL (the "Original Arrangement Agreement"), pursuant to which SNDL agreed to, among other things, acquire 32 cannabis retail stores operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the "Transaction") for a purchase price of $32.2 m

    12/15/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces Renewal of Share Repurchase Program

    EDMONTON, Alberta, Nov. 21, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") announced today that it has received approval from the Canadian Securities Exchange ("CSE") for the renewal of its share repurchase program (the "Share Repurchase Program"). The Share Repurchase Program authorizes the Company to repurchase up to C$100 million (the "Share Repurchase Amount") of its outstanding common shares ("shares") from time to time at prevailing market prices, enabling SNDL to opportunistically return value to shareholders. Pursuant to the Share Repurchase Program, SNDL may purchase shares from time to time at the discretion of management through open marke

    11/21/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Alliance Global Partners initiated coverage on SNDL Inc. with a new price target

    Alliance Global Partners initiated coverage of SNDL Inc. with a rating of Buy and set a new price target of $5.00

    9/3/25 7:54:28 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Canaccord Genuity resumed coverage on SNDL Inc.

    Canaccord Genuity resumed coverage of SNDL Inc. with a rating of Speculative Buy

    7/17/24 12:19:57 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    Sundial Growers upgraded by Canaccord Genuity with a new price target

    Canaccord Genuity upgraded Sundial Growers from Hold to Speculative Buy and set a new price target of $5.00

    8/16/22 7:59:34 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Financials

    Live finance-specific insights

    View All

    SNDL & 1CM Complete Purchase and Sale of 5 Retail Stores in Alberta and Saskatchewan

    EDMONTON, Alberta and TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") and 1CM Inc. (CSE:EPIC) (OTCQB:MILFF) (FSE: IQ70) ("1CM") are pleased to announce that SNDL has completed the acquisition of 5 cannabis retail stores located in Alberta and Saskatchewan from 1CM. The transaction represents the completion of the first closing pursuant to the amended and restated arrangement agreement dated December 15, 2025 (the "A&R Arrangement Agreement"). As previously announced, it is anticipated that the second (and final) closing will occur sometime in the first half of 2026, in respect of 27 additional cannabis retail stores located in Ontario, subject to obta

    1/7/26 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Reports Third Quarter 2025 Financial and Operational Results

    EDMONTON, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL" or the "Company") reported its financial and operational results for the third quarter ended September 30, 2025. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated. SNDL has also posted a supplemental investor presentation on its website, found at https://sndl.com. The Company will hold a conference call and webcast presentation at 10:00 a.m. EDT (8:00 a.m. MDT) on Tuesday, November 4, 2025. The conference call details can be found below. MANAGEMENT HIGHLIGHTS Net revenue: In the third quarter of 2025, net revenue totaled $24

    11/4/25 7:00:00 AM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL to Announce Third Quarter 2025 Financial Results on November 4, 2025

    EDMONTON, Alberta, Oct. 15, 2025 (GLOBE NEWSWIRE) -- SNDL Inc. (NASDAQ:SNDL, CSE:SNDL) ("SNDL") announced today that it will release its third quarter 2025 financial results for the period ended September 30, 2025, before market opens on Tuesday, November 4, 2025. Following the release of its third quarter results, SNDL will host a conference call and webcast at 10:00 a.m. EDT (8:00 a.m. MDT) on November 4, 2025. WEBCAST ACCESS To access the live webcast of the call, please visit the following link: https://edge.media-server.com/mmc/p/gutfgczk ABOUT SNDL INC.  SNDL Inc. (NASDAQ:SNDL, CSE:SNDL), through its wholly owned subsidiaries, is one of the largest vertically integrated cannabi

    10/15/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Leadership Updates

    Live Leadership Updates

    View All

    SNDL Announces 2025 Annual and Special Meeting Results

    EDMONTON, AB, July 31, 2025 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) (CSE:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual and Special Meeting of Shareholders (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at seven (7); (ii) electing each of Gregory Mills, J. Carlo Cannell, Lori Ell, Zachary George, Frank Krasovec, Bryan Pinney, and Gregory Turnbull as directors of the Company for the ensuing year; (iii) re-appointing CBIZ

    7/31/25 4:30:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Appoints New Chief Information Officer and New President, Liquor Division

    CALGARY, AB, Nov. 21, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the appointments of Phil McBride as Chief Information Officer and Navroop Sandhawalia as President, Liquor Division. "SNDL's success is driven by our commitment to talent density and our leaders are the foundation of our performance culture," said Zach George, Chief Executive Officer of SNDL.  "Phil's extensive expertise in technology and digital innovation, paired with Nav's financial acumen and best-in-class retail experience will further strengthen our executio

    11/21/24 6:02:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SNDL Announces 2024 Annual General Meeting Results

    CALGARY, AB, July 30, 2024 /PRNewswire/ - SNDL Inc. (NASDAQ:SNDL) ("SNDL" or the "Company") is pleased to announce the resolutions put to holders of common shares (the "Shareholders") at the Annual General Meeting (the "Meeting") were passed. At the Meeting, Shareholders approved: (i) fixing the number of directors of the board at six (6); (ii) electing each of Gregory Mills, Zachary George, Lori Ell, Frank Krasovec, Bryan Pinney and Gregory Turnbull as directors of the Company for the ensuing year; and (iii) re-appointing Marcum LLP as the auditors of the Company for the ensu

    7/30/24 5:45:00 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    $SNDL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    1/31/24 4:48:48 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Subject)

    2/14/23 5:28:02 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by SNDL Inc. (Amendment)

    SC 13G/A - SNDL Inc. (0001766600) (Filed by)

    2/13/23 4:06:09 PM ET
    $SNDL
    Medicinal Chemicals and Botanical Products
    Health Care